Ann: Change of Registry Address: Automic P/L - Sydney Office, page-5

A draw card, for me anyway, for investing into ptx is the concurrent trial strategy in place (besides others previous mentioned).
Also hold smaller parcels in two othe biotech, although the strategy above is not in force. The wait on the later required even more patience than on ptx.
For example, one trial ends it’s term and then thought to action via ethics, clinical placement ect begins (often 6 months to a year apart).
The obvious disadvantage is that of a speculative penny stock status (reflected by the SP)..., no licensing agreements, capital required and of course no incoming income (hence no dividend).
No answers here just facts.
Luck to holders.